Junevity

Junevity is an early-stage biotech developing a novel class of therapeutics using siRNA to reprogram cellular gene expression and reverse age-related diseases. The company's core innovation is the RESET platform, which integrates human omics data, genetic linkages, and machine learning to identify single transcription factor targets whose repression can reset cells to a healthier state. Founded by a team with expertise in siRNA, aging biology, and bioinformatics, and backed by venture capital, Junevity is advancing a preclinical pipeline with the long-term vision of creating a new era of disease reversal.

The RESET platform is an siRNA cell reprogramming platform that integrates human omics data, genetic linkages, and machine learning to identify master transcription factor targets. It aims to develop siRNA therapeutics that silence these targets to reprogram dysregulated gene expression networks back to a healthy state, thereby reversing complex, age-related diseases.

Junevity competes in the broad fields of RNA therapeutics, longevity biotech, and cellular reprogramming. Direct competitors include other startups targeting aging with RNAi or gene regulation (e.g., Korro Bio, Rejuvenate Bio). It also faces competition from large RNAi players (Alnylam) expanding into new indications and numerous companies targeting metabolic and neurodegenerative diseases with diverse modalities. Its differentiation lies in its specific focus on transcription factor repression for network-wide reprogramming.